Literature DB >> 8973169

Small molecule interactions with protein-tyrosine phosphatase PTP1B and their use in inhibitor design.

T R Burke1, B Ye, X Yan, S Wang, Z Jia, L Chen, Z Y Zhang, D Barford.   

Abstract

We have previously shown that a small peptide bearing the hydrolytically stable phosphotyrosyl (pTyr) mimetic, (difluorophosphonomethyl) phenylalanine (F2Pmp), is an extremely potent inhibitor of PTP1B, with an IC50 value of 100 nM [Burke, T. R., Kole, H. K., & Roller, P. P. (1994) Biochem. Biophys. Res. Commun. 204, 129-134]. We further demonstrated that removal of the peptide portion and incorporation of the difluorophosphonomethyl moiety onto a naphthalene ring system, but not a phenyl ring system, resulted in good inhibitory potency [Kole, H. K., Smyth, M. S., Russ, P. L., & Burke, T. R., Jr. (1995) Biochem, J. 311, 1025-1031]. In order to understand the structural basis for this inhibition, and to aid in the design of further analogs, we solved the X-ray structure of [1, 1-difluoro-1-(2-naphthalenyl)-methyl]phosphonic acid (6) complexed within the catalytic site of PTP1B, solved to 2.3 A resolution. In addition to showing the manner in which the phosphonate group is held within the catalytic site, the X-ray structure also revealed extensive hydrophobic interactions with the naphthalene ring system, beyond that possible with an analog bearing a single phenyl ring. It is further evident that, of the two fluorine atoms, the pro-R alpha-fluorine interacts with the enzyme to a significantly greater degree than the pro-S alpha-fluorine, forming a hydrogen bond to Phe 182. On the basis of a computer-assisted molecular modeling analysis, it was determined that addition of a hydroxyl to the naphthyl 4-position, giving [1, 1-difluoro-1-[2-(4-hydroxynaphthalenyl)] methyl]phosphonic acid (8), could potentially replace a water molecule situated in the PTP1B-6 complex, thereby allowing new hydrogen-bonding interactions with Lys 120 and Tyr 46. Compound 8 was therefore prepared and found to exhibit a doubling of affinity (Ki = 94 microM) relative to parent unsubstituted 6 (Ki = 179 microM), supporting, in principle, the development of high-affinity ligands based on molecular modeling analysis of the enzyme-bound parent.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8973169     DOI: 10.1021/bi961256d

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Structure-based prediction of free energy changes of binding of PTP1B inhibitors.

Authors:  Jing Wang; Shek Ling Chan; Kal Ramnarayan
Journal:  J Comput Aided Mol Des       Date:  2003-08       Impact factor: 3.686

2.  [Difluro(phosphono)methyl]phenylalanine-containing peptide inhibitors of protein tyrosine phosphatases.

Authors:  S Desmarais; R W Friesen; R Zamboni; C Ramachandran
Journal:  Biochem J       Date:  1999-01-15       Impact factor: 3.857

3.  A novel strategy for the development of selective active-site inhibitors of the protein tyrosine phosphatase-like proteins islet-cell antigen 512 (IA-2) and phogrin (IA-2beta).

Authors:  Paul G Drake; Günther H Peters; Henrik Sune Andersen; Wiljan Hendriks; Niels Peter H Møller
Journal:  Biochem J       Date:  2003-07-15       Impact factor: 3.857

4.  A highly efficient route to enantiomerically pure l-N-Bz-Pmp(t-Bu)2-OH and incorporation into a peptide-based protein tyrosine phosphatase inhibitor.

Authors:  Caitlin E Hubbard; Amy M Barrios
Journal:  Bioorg Med Chem Lett       Date:  2008-01-15       Impact factor: 2.823

5.  The anti-inflammatory compound BAY-11-7082 is a potent inhibitor of protein tyrosine phosphatases.

Authors:  Navasona Krishnan; Gyula Bencze; Philip Cohen; Nicholas K Tonks
Journal:  FEBS J       Date:  2013-05-09       Impact factor: 5.542

6.  Protein tyrosine phosphatase-1B (PTP1B) helps regulate EGF-induced stimulation of S-phase entry in human corneal endothelial cells.

Authors:  Yutaka Ishino; Cheng Zhu; Deshea L Harris; Nancy C Joyce
Journal:  Mol Vis       Date:  2008-01-16       Impact factor: 2.367

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.